66
BioLASCO Taiwan Co., Ltd.
6662.TWO · TWO
$28.50 +0.00% (+$0.00)
1M -1.04%
Market Cap $729.9M
P/E Ratio 17.85x
Div. Yield 5.44%
ROE 9.36%
Bulios Fair Price
$20.68
27.4% downside
Current Price
$28.5
Undervalued Fair Value Overvalued
According to Bulios Fair Price, 6662.TWO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
66 /100
Fair P/S 2.83x
P/E 17.85x
P/B 1.71x
Growth
23 /100
Declining FCF growth 12.52%
EPS growth 0.00%
Book val. growth 0.23%
Profitability
80 /100
Strong Op. margin 17.79%
Gross margin 38.95%
FCF margin 13.07%
Quality
44 /100
Average ROA 6.84%
ROIC 7.62%
Asset turnover 0.43x
Debt
100 /100
Low Int. coverage 28.06x
Debt/Equity 0.20x
Net debt/EBITDA 0.02x
Stability
69 /100
Stable EPS volatility 15.04%
Beta 0.17x
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about 6662.TWO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Yong-Hao Chen
Employees
91
Headquarters
Taipei